Specialty Pharma Journal Specialty, Precision & Technology
Merck has signed a multi-year collaboration agreement with privately-held NGM Biopharmaceuticals to develop novel biologic therapies in a wide range of therapeutic areas. NGM said that it has entered a five-year collaboration to research, develop and commercialize drugs that treat diabetes, obesity and nonalcoholic steatohepatitis (NASH). Merck will pay NGM …
Breaking News
- FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
- Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
- Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
- Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
- Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
- Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
- FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
- FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
- Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program